News

1 2 3 4 5 9 12 16
NEWS

SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer

  • DCVAC/OvCa decreased the risk of death in second line treatment of ovarian cancer by 62%.
  • Overall survival (OS) increased significantly by 13.4 months. Median Progression Free Survival (mPFS) increased by 1.8 months.
  • SOTIO plans to initiate a global Phase III study with DCVAC/OvCa.
NEWS

SOTIO to Present Final Phase II DCVAC/OvCa Data at the 2019 SGO Annual Meeting on Women's Cancer

SOTIO, a biotechnology company owned by the PPF Group, today announces that final data from the SOV02 Clinical Trial with DCVAC/OvCa will be presented in the plenary session as an oral presentation at the 2019 SGO’s 50th Annual Meeting on Women's Cancer. Final analysis of SOV02 data confirmed promising clinical efficacy of DCVAC/OvCa in patients with the 1st recurrence of ovarian cancer. SOTIO, a biotechnology company owned by the PPF Group, today announces that final data from the SOV02 Clinical Trial with DCVAC/OvCa will be presented in the plenary session as an oral presentation at the 2019 SGO’s 50th Annual Meeting on Women's Cancer. Final analysis of SOV02 data confirmed promising clinical efficacy of DCVAC/OvCa in patients with the 1st recurrence of ovarian cancer.

NEWS

SOTIO Appoints Dr. Harald Fricke as Chief Medical Officer

SOTIO, a biotechnology company owned by PPF Group, announces today the appointment of Harald Fricke, M.D., Ph.D. as Chief Medical Officer (CMO). Dr. Fricke has more than 30 years of experience in the field of immuno-oncology research and clinical development of new cancer therapies. At SOTIO, he will be responsible for clinical strategy and leading the expansion of SOTIO’s clinical-stage pipeline. 

>
This website uses cookies; by continuing to use this page, you consent to their use. About cookies